Search - tctmd.com

Displaying 261 - 280 of 1262

Sort: Relevancy | Date

News Daily News

Patients With CKD Remain Underrepresented in Trials of CV Meds

Todd Neale

March 08, 2024

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Presentation THT 2024

Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study

Presenter: Palak Shah

March 05, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Presentation THT 2024

Continue MCS for Another 14 days

Presenter: Manreet Kanwar

March 04, 2024

Presentation THT 2024

List for Urgent Transplant

Presenter: Tariq Ahmad

March 04, 2024

Presentation THT 2024

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

Presenter: Elena M. Donald

March 04, 2024

Presentation THT 2024

Cardiac Recovery in Response to Temporary Mechanical Circulatory Support

Presenter: Jane E. Wilcox

March 04, 2024

Presentation THT 2024

Cardiac Recovery in Response to GDMT

Presenter: Andreas Kalogeropoulos

March 04, 2024

Presentation THT 2024

Myocardial Recovery at the Level of the Single Myocyte

Presenter: Veli K. Topkara

March 04, 2024

Presentation THT 2024

Current Understanding of the Incidence, Characteristics, and Sustainability of "Recoverers" in Response to LVAD Support

Presenter: Emma Birks

March 04, 2024

Presentation THT 2024

Contemporary Pharmacological Therapies for Acute Heart Failure

Presenter: Wilfried Mullens

March 04, 2024

Presentation THT 2024

Left-to-Right Shunting for Chronic Heart Failure: Overview of the Device Landscape

Presenter: Benjamin Hibbert

March 04, 2024

News Daily News

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Todd Neale

March 04, 2024

Presentation THT 2024

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Presenter: Michael R. Zile

March 04, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Advertisement

Patients With CKD Remain Underrepresented in Trials of CV Meds

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

PH-HFpEF: Levosimendan

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study

Debating the Role of T-TEER in the Sickest Patients

Continue MCS for Another 14 days

List for Urgent Transplant

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

Cardiac Recovery in Response to Temporary Mechanical Circulatory Support

Cardiac Recovery in Response to GDMT

Myocardial Recovery at the Level of the Single Myocyte

Current Understanding of the Incidence, Characteristics, and Sustainability of "Recoverers" in Response to LVAD Support

Contemporary Pharmacological Therapies for Acute Heart Failure

Left-to-Right Shunting for Chronic Heart Failure: Overview of the Device Landscape

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

March 2024 Dispatch for the CV Team

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content